Global Monoclonal Antibody Therapeutics Market to Surge to $783.5 Billion by 2032

Monoclonal antibody therapeutics are moving into a new phase of accelerated expansion, powered by rising chronic disease prevalence, aging populations, and healthcare systems pivoting toward targeted, high value biologics. Parallel advances in antibody engineering and precision diagnostics are reshaping clinical practice and investment priorities across global markets.